Council for europe portal
Language : en Search
Choose language

Newsroom

Certification of suitability (CEP) / Procedure of certification (general) | News | 11 March 2019 | Strasbourg, France
The latest monthly activity report for the Certification of Substances Department (DCEP) is now available.
Certification of suitability (CEP) / CEP suspension | News | 04 February 2019 | Strasbourg, France
Following new information received recently about the presence of nitrosamine impurities in a drug substance covered by a certificate of suitability (CEP), the EDQM has taken immediate action and suspended CEP R1-CEP 2009-247-Rev 02/losartan potassium, form I, held by HETERO LABS, Limited, due to the detection of low levels of N-nitroso-N-methylamino butyric acid (NMBA) and N-nitroso-...
Products and Services | News | 24 January 2019 | Strasbourg, France
The 9.8 supplement of European Pharmacopoeia is now available and will be applicable in 38 European countries as from 01 July 2019.
Certification of suitability (CEP) / Procedure of certification (general) | News | 23 January 2019 | Strasbourg, France
Supplement 9.8 of the Ph. Eur is now available. CEP holders are invited to update their applications according to the revised monographs that will be implemented on the 1st of July 2019, and to follow the instructions given in the document.
Certification of suitability (CEP) / CEP suspension | News | 18 January 2019 | Strasbourg, France
Following new information received recently by EDQM about the presence of nitrosamine impurities in drug substances covered by certificates of suitability (CEPs), the EDQM has taken immediate actions on CEPs until appropriate corrective actions will have been implemented by the relevant company: due to the detection of low levels of N-nitrosodiethylamine (NDEA), suspension of the CEP R1-CEP 2010...
Certification of suitability (CEP) / Procedure of certification (general) | News | 08 January 2019 | Strasbourg, France
Users of CEPs are invited to provide comments on draft monographs published in Pharmeuropa 31.1 before 31st March 2019.
Certification of suitability (CEP) / Procedure of certification (general) | News | 14 December 2018 | Strasbourg, France
Following introduction of the revised Guideline on requirements for revision/renewal of Certificates of Suitability to the European Pharmacopeia Monographs’ (PA/PH/CEP (04) 2, 7R corr) several EDQM policy documents have been revised and are available.
Certification of suitability (CEP) / Chemical purity | News | 14 December 2018 | Strasbourg, France
The revised EDQM guideline Content of the dossier for chemical purity and microbiological quality, PA/PH/CEP (04) 1, 6R will enter into force in January 2019.
Certification of suitability (CEP) / Procedure of certification (general) | News | 20 November 2018 | Strasbourg, France
The revised EDQM ‘Guideline on requirements for revision/renewal of Certificates of Suitability to the European Pharmacopoeia Monographs’ (PA/PH/CEP (04) 2 7R) will enter into force in January 2019. Notable changes include the classification of changes related to the introduction of a new manufacturer of a starting material (see page 7), explicit reference to recent changes in the regulatory...
Certification of suitability (CEP) / CEP suspension | News | 19 November 2018 | Strasbourg, France
Following new information recently received by EDQM about the detection of low levels of N-nitrosodiethylamine (NDEA) in Valsartan manufactured by MYLAN LABORATORIES Ltd , the EDQM has immediately suspended the certificate of suitability (CEP) R1-CEP 2009-396-Rev 03/Valsartan held by this company, until appropriate corrective actions are taken.